BACKGROUND: Sleep disturbances are reportedly common among persons infected with human immunodeficiency virus (HIV), but recent data, including comparisons with HIV-uninfected persons, are limited. METHODS: We performed a cross-sectional study among early-treated HIV-infected military beneficiaries (n = 193) to determine the prevalence and factors associated with insomnia (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]). Data were compared with HIV-uninfected persons (n = 50) matched by age, sex, race or ethnicity, and military rank. RESULTS: Forty-six percent of HIV-infected persons had insomnia (PSQI >5), and 30% reported daytime drowsiness (ESS ≥10). The prevalence of insomnia and daytime sleepiness was not significantly higher compared with the HIV-uninfected group (38% [P = .30] and 20% [P = .18], respectively). In the multivariate model, factors associated with insomnia among HIV infected patients included depression (odds ratio [OR], 16.8; 95% confidence interval [CI], 2.0-142.1; P = .01), increased waist size (OR, 2.7; 95% CI, 1.4-5.1; P = .002), and fewer years of education (OR, 0.8; 95% CI, .7-.95; P = .006). Neurocognitive impairment (diagnosed in 19% of HIV-infected participants) was not associated with insomnia; however, HIV-infected persons with insomnia were 3.1-fold more likely to have a decline in activities of daily living than those without insomnia (23% vs 9%; P = .01). Only 18% of HIV-infected persons reported using a sleep medication at least weekly. CONCLUSIONS: HIV-infected persons have a high prevalence of insomnia, but among an early-treated cohort this rate was not significantly higher compared with HIV-uninfected persons. Factors associated with insomnia among HIV-infected patients include depression and increased waist size. Prompt diagnosis and treatment of sleep disturbances are advocated and may improve quality of life.
BACKGROUND:Sleep disturbances are reportedly common among persons infected with human immunodeficiency virus (HIV), but recent data, including comparisons with HIV-uninfectedpersons, are limited. METHODS: We performed a cross-sectional study among early-treated HIV-infected military beneficiaries (n = 193) to determine the prevalence and factors associated with insomnia (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]). Data were compared with HIV-uninfectedpersons (n = 50) matched by age, sex, race or ethnicity, and military rank. RESULTS: Forty-six percent of HIV-infectedpersons had insomnia (PSQI >5), and 30% reported daytime drowsiness (ESS ≥10). The prevalence of insomnia and daytime sleepiness was not significantly higher compared with the HIV-uninfected group (38% [P = .30] and 20% [P = .18], respectively). In the multivariate model, factors associated with insomnia among HIV infectedpatients included depression (odds ratio [OR], 16.8; 95% confidence interval [CI], 2.0-142.1; P = .01), increased waist size (OR, 2.7; 95% CI, 1.4-5.1; P = .002), and fewer years of education (OR, 0.8; 95% CI, .7-.95; P = .006). Neurocognitive impairment (diagnosed in 19% of HIV-infectedparticipants) was not associated with insomnia; however, HIV-infectedpersons with insomnia were 3.1-fold more likely to have a decline in activities of daily living than those without insomnia (23% vs 9%; P = .01). Only 18% of HIV-infectedpersons reported using a sleep medication at least weekly. CONCLUSIONS:HIV-infectedpersons have a high prevalence of insomnia, but among an early-treated cohort this rate was not significantly higher compared with HIV-uninfectedpersons. Factors associated with insomnia among HIV-infectedpatients include depression and increased waist size. Prompt diagnosis and treatment of sleep disturbances are advocated and may improve quality of life.
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: Lucía Gallego; Pablo Barreiro; Rafael del Río; Daniel González de Requena; Apolinar Rodríguez-Albariño; Juan González-Lahoz; Vincent Soriano Journal: Clin Infect Dis Date: 2004-01-09 Impact factor: 9.079
Authors: M Núñez; D González de Requena; L Gallego; I Jiménez-Nácher; J González-Lahoz; V Soriano Journal: J Acquir Immune Defic Syndr Date: 2001-12-01 Impact factor: 3.731
Authors: Martin J Downing; Steven T Houang; Roberta Scheinmann; Irene S Yoon; Mary Ann Chiasson; Sabina Hirshfield Journal: Sleep Health Date: 2016-09-19
Authors: Md Dilshad Manzar; Peter Sony; Mohammed Salahuddin; Abera Kumalo; Mathewos Geneto; Seithikurippu R Pandi-Perumal; Adam Moscovitch; Ahmed S BaHammam Journal: Sleep Sci Date: 2017 Apr-Jun
Authors: Eeeseung Byun; Caryl L Gay; Carmen J Portillo; Clive R Pullinger; Bradley E Aouizerat; Kathryn A Lee Journal: Sleep Med Date: 2017-01-20 Impact factor: 3.492
Authors: Shia T Kent; Greer A Burkholder; Gabriel S Tajeu; E Turner Overton; Paul Muntner Journal: Curr Hypertens Rep Date: 2015-11 Impact factor: 5.369